Hello guest, Register  |  Sign In
Virologica Sinica, 32 (4) : 271, 2017
Research Article
Drug resistance mutation profiles of the drug-naïve and first-line regimen-treated HIV-1-infected population of Suzhou,China
1. Research Group of HIV-1 Molecular Epidemiology and Virology, The State Key Laboratory of Virology, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan 430071, China
2. University of Chinese Academy of Sciences, Beijing 100000, China
3. Division of HIV-1/AIDS, the Fifth People's Hospital of Suzhou, Suzhou 215000, China
4. Department of Microbiology and Immunology, Schulich School of Medicine & Dentistry, University of Western Ontario, London N6A 5C1, Canada
 Correspondence: zhuchw@126.com;sunbl@wh.iov.cn
(465.20KB)  (1460.13KB)  
Abstract
Little is known about the prevalence of drug-resistant mutations in HIV-1-positive individuals in Suzhou,China.To elucidate the transmitted drug resistance (TDR) and acquired drug resistance mutation (ADR) profiles,we collected blood specimens from 127 drug-naïve and 117 first-line drugtreated HIV-1-infected individuals sampled from 2014 to 2016 in Suzhou.We successfully amplified pol fragments from 100 drug-naïve and 20 drug-treated samples.We then determined the drugresistant mutations to protease (PR) and reverse-transcriptase (RT) inhibitors according to the Stanford drug resistance database.Overall,11 and 13 individuals had transmitted (drug-naïve group) and acquired (treated group) resistance mutations,respectively.Six transmitted drugresistant mutations were found,including two mutations (L33F and L76V) in the protease region and four (K70N/E and V179D/E) in the RT region.Only L76V was a major mutation,and K70N/E and V179D/E are known to cause low-level resistance to RT inhibitors.All 13 treated participants who had major drug resistance mutations demonstrated intermediate to high resistance to efavirenz and nevirapine,and six had a treatment duration of less than three months.No major mutations to RT inhibitors were found,implying that the epidemic of transmitted resistance mutations was not significant in this area.Our results suggest that more frequent virus load and drug resistance mutation tests should be conducted for individuals receiving antiretroviral treatment,especially for newly treated patients.Our research provides insights into the occurrence of HIV-1 drug resistance in Suzhou and will help to optimize the treatment strategy for this population.
Received: 19 Apr 2017  Accepted: 5 Jul 2017  Published online: 7 Aug 2017
Home |  Resources |  About Us |  Support |  Contact Us |  Privacy |  Powered by CanSpeed | 
Copyright © 2015 Virologica Sinica. All rights reserved